Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBIT Margin (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed EBIT Margin for 8 consecutive years, with 558.64% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 182723.0% year-over-year to 558.64%, compared with a TTM value of 9686.71% through Sep 2025, down 646208.0%, and an annual FY2024 reading of 26234.0%, down 2265011.0% over the prior year.
  • EBIT Margin was 558.64% for Q3 2025 at Bicycle Therapeutics, up from 2965.82% in the prior quarter.
  • Across five years, EBIT Margin topped out at 331.81% in Q4 2023 and bottomed at 2965.82% in Q2 2025.
  • Average EBIT Margin over 5 years is 830.94%, with a median of 703.66% recorded in 2025.
  • The sharpest move saw EBIT Margin skyrocketed 186954bps in 2022, then plummeted -246751bps in 2025.
  • Year by year, EBIT Margin stood at 2253.0% in 2021, then surged by 83bps to 383.46% in 2022, then surged by 187bps to 331.81% in 2023, then dropped by -6bps to 312.72% in 2024, then tumbled by -279bps to 558.64% in 2025.
  • Business Quant data shows EBIT Margin for BCYC at 558.64% in Q3 2025, 2965.82% in Q2 2025, and 703.66% in Q1 2025.